Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineThe Motley Fool • Tuesday
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • Monday
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026PRNewsWire • 10/23/26
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026PRNewsWire • 10/19/26
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings StorySeeking Alpha • 10/15/26
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1BMarketBeat • 09/20/26
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeeking Alpha • 09/16/26
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/10/26
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEAPRNewsWire • 08/31/26
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesPRNewsWire • 08/27/26
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric CancerZacks Investment Research • 08/26/26
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesPRNewsWire • 08/26/26
Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA TranscriptSeeking Alpha • 08/26/26